2024 ICD-10-CM Diagnosis Code T48.6X6A

Underdosing of antiasthmatics, initial encounter

ICD-10-CM Code:
T48.6X6A
ICD-10 Code for:
Underdosing of antiasthmatics, initial encounter
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system
        (T48)

T48.6X6A is a billable diagnosis code used to specify a medical diagnosis of underdosing of antiasthmatics, initial encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T48.6X6A is an initial encounter code, includes a 7th character and should be used while the patient is receiving active treatment for a condition like underdosing of antiasthmatics. According to ICD-10-CM Guidelines an "initial encounter" doesn't necessarily means "initial visit". The 7th character should be used when the patient is undergoing active treatment regardless if new or different providers saw the patient over the course of a treatment. The appropriate 7th character codes should also be used even if the patient delayed seeking treatment for a condition.

Clinical Classification

Clinical Information

  • Albuterol

    a short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat asthma. albuterol is prepared as a racemic mixture of r(-) and s(+) stereoisomers. the stereospecific preparation of r(-) isomer of albuterol is referred to as levalbuterol.
  • Albuterol, Ipratropium Drug Combination

    a combined pharmaceutical preparation of ipratropium bromide and albuterol sulfate that is used to treat the symptoms of asthma and chronic obstructive pulmonary disease.
  • Aminophylline

    a drug combination that contains theophylline and ethylenediamine. it is more soluble in water than theophylline but has similar pharmacologic actions. it's most common use is in bronchial asthma, but it has been investigated for several other applications.
  • Choline

    a basic constituent of lecithin that is found in many plants and animal organs. it is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
  • Choline Deficiency

    a condition produced by a deficiency of choline in animals. choline is known as a lipotropic agent because it has been shown to promote the transport of excess fat from the liver under certain conditions in laboratory animals. combined deficiency of choline (included in the b vitamin complex) and all other methyl group donors causes liver cirrhosis in some animals. unlike compounds normally considered as vitamins, choline does not serve as a cofactor in enzymatic reactions. (from saunders dictionary & encyclopedia of laboratory medicine and technology, 1984)
  • Choline Dehydrogenase

    an enzyme bound to the inner mitochondrial membrane that catalyzes the oxidation of choline to betaine.
  • Choline Kinase

    an enzyme that is active in the first step of choline phosphoglyceride (lecithin) biosynthesis by catalyzing the phosphorylation of choline to phosphorylcholine in the presence of atp. ethanolamine and its methyl and ethyl derivatives can also act as acceptors. ec 2.7.1.32.
  • Choline O-Acetyltransferase

    an enzyme that catalyzes the formation of acetylcholine from acetyl-coa and choline. ec 2.3.1.6.
  • Choline-Phosphate Cytidylyltransferase

    an enzyme that catalyzes the transfer of cytidylate (cmp) to choline phosphate to form cdpcholine. it is the rate-limiting enzyme in the choline pathway for the biosynthesis of phosphatidylcholine. its activity is increased by glucocorticoids. ec 2.7.7.15.
  • Cholinergic Agents

    any drug used for its actions on cholinergic systems. included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons. the term cholinergic agents is sometimes still used in the narrower sense of muscarinic agonists, although most modern texts discourage that usage.
  • Cholinergic Agonists

    drugs that bind to and activate cholinergic receptors.
  • Cholinergic Antagonists

    drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
  • Cholinergic Fibers

    nerve fibers liberating acetylcholine at the synapse after an impulse.
  • Cholinergic Neurons

    neurons whose primary neurotransmitter is acetylcholine.
  • Cholinesterase Inhibitors

    drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.
  • Cholinesterase Reactivators

    drugs used to reverse the inactivation of cholinesterase caused by organophosphates or sulfonates. they are an important component of therapy in agricultural, industrial, and military poisonings by organophosphates and sulfonates.
  • Cholinesterases

  • Cytidine Diphosphate Choline

    donor of choline in biosynthesis of choline-containing phosphoglycerides.
  • Diacylglycerol Cholinephosphotransferase

    an enzyme that catalyzes the synthesis of phosphatidylcholines from cdpcholine and 1,2-diacylglycerols. ec 2.7.8.2.
  • Glycerylphosphorylcholine

    a component of phosphatidylcholines or lecithins, in which the two hydroxy groups of glycerol are esterified with fatty acids. (from stedman, 26th ed)
  • Leukemia Inhibitory Factor

    an interleukin-6 related cytokine that exhibits pleiotrophic effects on many physiological systems that involve cell proliferation, differentiation, and survival. leukemia inhibitory factor binds to and acts through the lif receptor.
  • Muscarinic Agonists

    drugs that bind to and activate muscarinic cholinergic receptors (receptors, muscarinic). muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the gi tract, urinary bladder and the eye. they may also be used to reduce heart rate.
  • Muscarinic Antagonists

    drugs that bind to but do not activate muscarinic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists. muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, gi system, and salivary glands, gi motility, urinary bladder tone, and the central nervous system.
  • Neuroimmunomodulation

    the biochemical and electrophysiological interactions between the nervous system and immune system.
  • Nicotinic Agonists

    drugs that bind to and activate nicotinic cholinergic receptors (receptors, nicotinic). nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission.
  • Non-Neuronal Cholinergic System

    the system of acetylcholine-synthesizing enzymes, transporters, receptors and degrading enzymes that characterize non-neuronal cholinergic cells such as airway and skin epithelial cells.
  • Phosphatidylcholines

    derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a choline moiety.
  • Phosphorylcholine

    calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
  • Receptors, Cholinergic

    cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology.
  • Clenbuterol

    a substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. it is used as a bronchodilator in asthma.
  • Fenoterol

    a synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
  • Hexoprenaline

    stimulant of adrenergic beta 2 receptors. it is used as a bronchodilator, antiasthmatic agent, and tocolytic agent.
  • Isoproterenol

    isopropyl analog of epinephrine; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. it is used mainly as bronchodilator and heart stimulant.
  • Levalbuterol

    the r-isomer of albuterol.
  • Nedocromil

    a pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils; neutrophils; macrophages; mast cells; monocytes; and platelets.
  • Terbutaline

    a selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.
  • Theophylline

    a methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. theophylline inhibits the 3',5'-cyclic nucleotide phosphodiesterase that degrades cyclic amp thus potentiates the actions of agents that act through adenylyl cyclases and cyclic amp.
  • Tretoquinol

    an adrenergic beta-agonist used as a bronchodilator agent in asthma therapy.

Coding Guidelines

Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system (T48). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Convert T48.6X6A to ICD-9-CM

  • ICD-9-CM Code: -
    No Map Flag -

Table of Drugs and Chemicals

The parent code T48.6X6 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
Acefylline piperazineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
AcepifyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
AlbuterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
AmbuphyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
AminophyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
AmlexanoxT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Antiasthmatic drug NECT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
BambuterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
BamifyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
BitolterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Bronchodilator NECT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
BroxaterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
BufrolinT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
BufyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
ButetamateT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
CarbuterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
CholineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Choline
  »chloride
T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Choline
  »dihydrogen citrate
T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Choline
  »salicylate
T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Choline
  »theophyllinate
T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
ClenbuterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
ClorprenalineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Cromoglicic acidT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
CromolynT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
DoxantrazoleT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
EnprofyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
EtafedrineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
EtamiphyllinT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Ethylenediamine theophyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
EthylnorepinephrineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
FenoterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
FlunisolideT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Flutropium bromideT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Folium stramoniaeT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
GlyphyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
HexoprenalineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
IbuterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Ipratropium (bromide)T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
IsoetarineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
IsoprenalineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
IsoproterenolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
LevalbuterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
LevoproxyphyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
MethoxyphenamineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
NedocromilT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Oxitropium bromideT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
OxtriphyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Pemirolast (potassium)T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
PirbuterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
ProtokylolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
ProxyphyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
ReproterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
RimiterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
SalbutamolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
SalmeterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
StramoniumT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Stramonium
  »natural state
T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
TerbutalineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Theobromine (calcium salicylate)T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Theobromine (calcium salicylate)
  »sodium salicylate
T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
TheophyllamineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
TheophyllineT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Theophylline
  »aminobenzoic acid
T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Theophylline
  »ethylenediamine
T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
Theophylline
  »piperazine p-amino-benzoate
T48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
TretoquinolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6
TulobuterolT48.6X1T48.6X2T48.6X3T48.6X4T48.6X5T48.6X6

Patient Education


Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

  • Knowing your medicines. When you get a prescription, ask the name of the medicine and check to make sure that the pharmacy gave you the right medicine. Make sure that you understand how often you should take the medicine and how long you should take it.
  • Keeping a list of medicines.
    • Write down all of the medicines that you are taking, including the names of your medicines, how much you take, and when you take them. Make sure to include any over-the-counter medicines, vitamins, supplements, and herbs that you take.
    • List the medicines that you are allergic to or that have caused you problems in the past.
    • Take this list with you every time you see a health care provider.
  • Reading medicine labels and following the directions. Don't just rely on your memory - read the medication label every time. Be especially careful when giving medicines to children.
  • Asking questions. If you don't know the answers to these questions, ask your health care provider or pharmacist:
    • Why am I taking this medicine?
    • What are the common side effects?
    • What should I do if I have side effects?
    • When should I stop this medicine?
    • Can I take this medicine with the other medicines and supplements on my list?
    • Do I need to avoid certain foods or alcohol while taking this medicine?

Food and Drug Administration


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.